Fresenius Faces French Damages Over Alimta
Eli Lilly Claims Victory In Dispute On Pemetrexed Patent
Fresenius Kabi must pay Eli Lilly €28m in damages after a French court of first instance found that the generics firm’s pemetrexed infringed intellectual property protecting the Alimta chemotherapy brand. The German firm has commented on possible next steps.
